RenovoRx, Inc. (RNXT)

NASDAQ: RNXT · IEX Real-Time Price · USD
2.68
+0.05 (1.90%)
Feb 1, 2023, 9:30 AM EST - Market open
1.9%
Market Cap 23.47M
Revenue (ttm) n/a
Net Income (ttm) -10.09M
Shares Out 9.10M
EPS (ttm) -0.98
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 217
Open 2.68
Previous Close 2.63
Day's Range 2.68 - 2.68
52-Week Range 1.50 - 5.00
Beta n/a
Analysts Buy
Price Target 10.20 (+280.6%)
Earnings Date n/a

About RNXT

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California. [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Aug 26, 2021
Employees 10
Stock Exchange NASDAQ
Ticker Symbol RNXT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for RNXT stock is "Buy." The 12-month stock price forecast is $10.2, which is an increase of 280.60% from the latest price.

Price Target
$10.2
(280.60% upside)
Analyst Consensus: Buy
Stock Forecasts

News

RenovoRx to Present at the Sequire Biotechnology Virtual Conference on February 2, 2023

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, today announced that Shaun Bagai, Chief Executive O...

1 week ago - Business Wire

RenovoRx Announces Initial Results in Pharmacokinetic (PK) Substudy: Data on RenovoGem™ Supports Potential for RenovoTAMP® Therapy Platform to Increase Local Gemcitabine (Chemotherapy) Delivery and Decrease Side Effects of Pancreatic Cancer Treatment

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, today announced initial results from a pharmacokine...

2 weeks ago - Business Wire

RenovoRx Strengthens Intellectual Property (IP) Portfolio with Eighth US Patent

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors, today announced that on January ...

3 weeks ago - Business Wire

RenovoRx Announces Acceptance of Four Clinical Data Abstracts at the 2023 ASCO Gastrointestinal Cancers (ASCO GI) Symposium

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors, today announced the acceptance o...

1 month ago - Business Wire

RenovoRx Announces Presentations at the Advanced Interventional Management Symposium (AIMsymposium) Highlighting its Innovative RenovoTAMP® Therapy Platform for Targeted Treatment of Cancers

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx ...

2 months ago - Business Wire

RenovoRx Reports Third Quarter 2022 Financial Results

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx ...

2 months ago - Business Wire

RenovoRx to Participate in Upcoming October 2022 Investor Conferences

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Tr...

4 months ago - Business Wire

RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology (CIO) Highlighting its Innovative Therapy Platform for Targeted Treatment of Pancreatic Cancer

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Tr...

4 months ago - Business Wire

RenovoRx Appoints Angela Gill Nelms as Chief Operating Officer

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Tr...

4 months ago - Business Wire

RenovoRx to Participate in the H.C. Wainwright 24th Annual Global Investment Conference, September 12-14, 2022

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Tr...

5 months ago - Business Wire

RenovoRx Reports Second Quarter 2022 Financial Results

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Tr...

6 months ago - Business Wire

RenovoRx Appoints James Ahlers as Chief Financial Officer

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today is announcing the appointment of James Ahlers as Chief Fi...

7 months ago - Business Wire

RenovoRx Launches “The RenovoRx Story” Video Series

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced the launch of a n...

7 months ago - Business Wire

RenovoRx and TIGeR-PaC Leadership to Host RenovoTAMP™ Webinar on June 21, 2022

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced that they will host a webinar highlighting thei...

8 months ago - Business Wire

RenovoRx to Participate in the University of Cambridge's Academy of Therapeutic Sciences Gateway to Translation Seminar Series on June 8, 2022

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced that it will participate in the Gateway to Tran...

8 months ago - Business Wire

RenovoRx to Present Preclinical Research Data Demonstrating its Innovative Therapy Platform's Potential Utility for the Treatment of Bile Duct Cancer

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announces that it will pres...

9 months ago - Business Wire

RenovoRx to Participate in Upcoming H.C Wainwright Global Investment Conference in May 2022

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced management's part...

9 months ago - Business Wire

RenovoRx Reports First Quarter 2022 Financial Results

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today is reporting its financial ...

9 months ago - Business Wire

RenovoRx Sponsors Pancreatic Cancer Action Network's PurpleStride Event to End Pancreatic Cancer

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, announced today it will join the ...

10 months ago - Business Wire

RenovoRx Reports Full Year 2021 Financial Results

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today is reporting its financial ...

11 months ago - Business Wire

RenovoRx to Participate in March 2022 Investor Conferences

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced its leadership's ...

11 months ago - Business Wire

RenovoRx Enrolls First Pancreatic Cancer Patient at Columbia University's New York-Presbyterian Hospital Irving Medical Center in Ongoing TIGeR-PaC Phase 3 Clinical Trial

NEW YORK & LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced enroll...

1 year ago - Business Wire

RenovoRx to Host “Delivering Therapy Where it Matters” Fireside Chat with CEO, Shaun Bagai, on February 23rd at 12 P.M. ET

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, will host the “Delivering Therapy...

1 year ago - Business Wire

RenovoRx Announces Presentation at the 2022 SPECTRUM Conference Highlighting Its Innovative RenovoTAMP™ Therapy for Targeted Treatment of Cancer

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced that Dr. Ripal Ga...

1 year ago - Business Wire